Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish
- PMID: 25619798
- PMCID: PMC4515405
- DOI: 10.1017/S1092852914000686
Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish
Abstract
This article reviews the antidepressant actions of ketamine, an N-methyl-D-aspartame glutamate receptor (NMDAR) antagonist, and offers a potential neural mechanism for intranasal ketamine's ultra-rapid actions based on the key role of NMDAR in the nonhuman primate prefrontal cortex (PFC). Although intravenous ketamine infusions can lift mood within hours, the current review describes how intranasal ketamine administration can have ultra-rapid antidepressant effects, beginning within minutes (5-40 minutes) and lasting hours, but with repeated treatments needed for sustained antidepressant actions. Research in rodents suggests that increased synaptogenesis in PFC may contribute to the prolonged benefit of ketamine administration, beginning hours after administration. However, these data cannot explain the relief that occurs within minutes of intranasal ketamine delivery. We hypothesize that the ultra-rapid effects of intranasal administration in humans may be due to ketamine blocking the NMDAR circuits that generate the emotional representations of pain (eg, Brodmann Areas 24 and 25, insular cortex), cortical areas that can be overactive in depression and which sit above the nasal epithelium. In contrast, NMDAR blockade in the dorsolateral PFC following systemic administration of ketamine may contribute to cognitive deficits. This novel view may help to explain how intravenous ketamine can treat the symptoms of depression yet worsen the symptoms of schizophrenia.
Keywords: Antidepressant; area 25; glutamate; prefrontal cortex; rTMS.
Figures



Similar articles
-
Ketamine: The final frontier or another depressing end?Behav Brain Res. 2020 Apr 6;383:112508. doi: 10.1016/j.bbr.2020.112508. Epub 2020 Feb 1. Behav Brain Res. 2020. PMID: 32017978 Free PMC article. Review.
-
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.Neuropharmacology. 2016 Jan;100:17-26. doi: 10.1016/j.neuropharm.2015.07.028. Epub 2015 Jul 26. Neuropharmacology. 2016. PMID: 26211972 Review.
-
Ketamine for Treatment-Resistant Depression: a New Advocate.Rev Invest Clin. 2018;70(2):65-7. doi: 10.24875/RIC.18002501. Rev Invest Clin. 2018. PMID: 29718013
-
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. J Affect Disord. 2014. PMID: 24388038 Review.
-
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.Pharmacol Biochem Behav. 2019 Jun;181:53-59. doi: 10.1016/j.pbb.2019.04.008. Epub 2019 Apr 26. Pharmacol Biochem Behav. 2019. PMID: 31034852
Cited by
-
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review.Ther Adv Psychopharmacol. 2023 Feb 7;13:20451253231151327. doi: 10.1177/20451253231151327. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 36776623 Free PMC article. Review.
-
Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression.Front Neurosci. 2023 Aug 8;17:1223145. doi: 10.3389/fnins.2023.1223145. eCollection 2023. Front Neurosci. 2023. PMID: 37614344 Free PMC article. Review.
-
Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.Neurobiol Learn Mem. 2020 Dec;176:107327. doi: 10.1016/j.nlm.2020.107327. Epub 2020 Oct 17. Neurobiol Learn Mem. 2020. PMID: 33075480 Free PMC article. Review.
-
NMDAR Neurotransmission Needed for Persistent Neuronal Firing: Potential Roles in Mental Disorders.Front Psychiatry. 2021 Apr 9;12:654322. doi: 10.3389/fpsyt.2021.654322. eCollection 2021. Front Psychiatry. 2021. PMID: 33897503 Free PMC article. Review.
-
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives.Psychiatry Investig. 2020 Mar;17(3):181-192. doi: 10.30773/pi.2019.0236. Epub 2020 Mar 23. Psychiatry Investig. 2020. PMID: 32209965 Free PMC article.
References
-
- Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36(2):186–197. - PubMed
-
- Andolfatto G, Willman E, Joo D, et al. Intranasal ketamine for analgesia in the emergency department: a prospective observational series. Acad Emerg Med. 2013;20(10):1050–1054. - PubMed
-
- McCarty EC, Mencio GA, Walker LA, Green NE. Ketamine sedation for the reduction of children’s fractures in the emergency department. J Bone Joint Surg Am. 2000;82-A(7):912–918. - PubMed
-
- Moretti RJ, Hassan SZ, Goodman LI, Meltzer HY. Comparison of ketamine and thiopental in healthy volunteers: effects on mental status, mood, and personality. Anesth Analg. 1984;63(12):1087–1096. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous